For example, the lncRNA PCA3 in urine has been approved by the US Food and Drug Administration (FDA) as a urine marker for prostate cancer because of its better sensitivity and specificity than prostate-specific antigen (PSA) [20,21,22]. This evidence concerns the gene KLK3 and prostate carcinoma.